articles on psycho-​social aspects of mental illness and the DSM

6994

paint­ing by Wass­ily Kandinsky

Psy­chi­a­trists under fire in men­tal health bat­tle by Jamie Doward in the guardian

In a ground­break­ing move that has already prompted a fierce back­lash from psy­chi­a­trists, the British Psy­cho­log­i­cal Society’s divi­sion of clin­i­cal psy­chol­ogy (DCP) will on Mon­day issue a state­ment declar­ing that, given the lack of evi­dence, it is time for a “par­a­digm shift” in how the issues of men­tal health are under­stood. The state­ment effec­tively casts doubt on psychiatry’s pre­dom­i­nantly bio­med­ical model of men­tal dis­tress – the idea that peo­ple are suf­fer­ing from ill­nesses that are treat­able by doc­tors using drugs. The DCP said its deci­sion to speak out “reflects fun­da­men­tal con­cerns about the devel­op­ment, per­sonal impact and core assump­tions of the (diag­no­sis) sys­tems”, used by psychiatry.

Dr Lucy John­stone, a con­sul­tant clin­i­cal psy­chol­o­gist who helped draw up the DCP’s state­ment, said it was unhelp­ful to see men­tal health issues as ill­nesses with bio­log­i­cal causes.

On the con­trary, there is now over­whelm­ing evi­dence that peo­ple break down as a result of a com­plex mix of social and psy­cho­log­i­cal cir­cum­stances – bereave­ment and loss, poverty and dis­crim­i­na­tion, trauma and abuse,” John­stone said. The provoca­tive state­ment by the DCP has been timed to come out shortly before the release of DSM-​5, the fifth edi­tion of the Amer­i­can Psy­chi­a­try Association’s Diag­nos­tic and Sta­tis­ti­cal Man­ual of Men­tal Disorders.

The man­ual has been attacked for expand­ing the range of men­tal health issues that are clas­si­fied as dis­or­ders. For exam­ple, the fifth edi­tion of the book, the first for two decades, will clas­sify man­i­fes­ta­tions of grief, tem­per tantrums and wor­ry­ing about phys­i­cal ill-​health as the men­tal ill­nesses of major depres­sive dis­or­der, dis­rup­tive mood dys­reg­u­la­tion dis­or­der and somatic symp­tom dis­or­der, respectively.

Some of the manual’s omis­sions are just as con­tro­ver­sial as the manual’s inclu­sions. The term “Asperger’s dis­or­der” will not appear in the new man­ual, and instead its symp­toms will come under the newly added “autism spec­trum disorder”.

The DSM is used in a num­ber of coun­tries to vary­ing degrees. Britain uses an alter­na­tive man­ual, the Inter­na­tional Clas­si­fi­ca­tion of Dis­eases (ICD) pub­lished by the World Health Organ­i­sa­tion, but the DSM is still hugely influ­en­tial – and controversial.

The writer Oliver James, who trained as a clin­i­cal psy­chol­o­gist, wel­comed the DCP’s deci­sion to speak out against psy­chi­atric diag­no­sis and stressed the need to move away from a bio­med­ical model of men­tal dis­tress to one that exam­ined soci­etal and per­sonal factors.

Do we need to change the way we are think­ing about men­tal ill­ness? fol­low­ing quote by Oliver James in the Guardian

A stu­dent friend of mine once started claim­ing that she was being con­trolled by elec­tri­cal impulses beamed across the city by “author­i­tar­ian cap­i­tal­ists”. She spent hours in the bath, clean­ing herself.

Fol­low­ing her removal to an asy­lum, her par­ents arrived to col­lect her pos­ses­sions. Nearly all of her (mostly clean) clothes were deemed so “soiled” they would need to be burnt. The room was obses­sively cleaned. Her father was a health inspector.

Within the med­ical model of men­tal ill­ness, she had inher­ited genes pre­dis­pos­ing her to obses­sive rit­u­als and to psy­chosis. The model does not enter­tain the pos­si­bil­ity that the health inspector’s intru­sive­ness dis­tressed her or, as it turned out, that he had sex­u­ally abused her.

Yet 13 stud­ies find that more than half of schiz­o­phren­ics suf­fered child­hood abuse. Another review of 23 stud­ies shows that schiz­o­phren­ics are at least three times more likely to have been abused than non-​schizophrenics. It is becom­ing appar­ent that abuse is the major cause of psy­choses. It is also all too clear that the med­ical model is bust.

In the press release accom­pa­ny­ing pub­li­ca­tion of DSM-​5, David Kupfer, who over­saw its cre­ation, states: “We’ve been telling patients for sev­eral decades that we are wait­ing for bio­mark­ers. We’re still wait­ing.” This is an aston­ish­ing admis­sion that there are no reli­able genetic or neu­ro­log­i­cal mea­sure­ments that dis­tin­guish a per­son with men­tal illness.

While there is some evi­dence that the electro-​chemistry of dis­tressed peo­ple can be dif­fer­ent from the undis­tressed, the Human Genome Project seems to be prov­ing that genes play almost no part in caus­ing this. Eleven years of care­ful study of our DNA shows that dif­fer­ences in it do not explain men­tal ill­ness, hardly at all. If one sib­ling is anx­ious or depressed and another is not, at most, dif­fer­ences in DNA can only explain 1 – 5% of why it is one and not the other.

Of course, some researchers main­tain that, given more time (and money), they will still come up with sig­nif­i­cant results. But off the record, nearly all mol­e­c­u­lar geneti­cists admit that it now really does look as if dif­fer­ences in DNA will explain very little.

By con­trast, there is a huge body of evi­dence that our early child­hood expe­ri­ences com­bined with sub­se­quent expo­sure to adver­sity explain a very great deal. This is dose depen­dent: the more mal­treat­ment, the ear­lier you suf­fer it and the worse it is, the greater your risk of adult emo­tional dis­tress. These expe­ri­ences set our electro-​chemical thermostats.

So does sub­se­quent adult adver­sity. For instance, a per­son with six or more per­sonal debts is six times more likely to be men­tally ill than some­one with none, regard­less of their social class: the more debts, the greater the risk.

We need fun­da­men­tal changes in how our soci­ety is organ­ised to give par­ents the best chance of meet­ing the needs of chil­dren and to pre­vent the amount of adult adversity.

Britons and Amer­i­cans have exactly twice the amount of men­tal ill­ness of main­land west­ern Euro­peans (23% ver­sus 11.5%). Thirty years of Thatcher and “Blatcher” turned us into a nation of “affluenza”-stricken, shop-​till-​you-​drop, “it could be you”, credit-​fuelled con­sumer junkies. Per­sonal debt – a major stres­sor for adults – rose from £200bn in 1980 to £1,400bn in 2006. After 1979, the amount of men­tal ill­ness mushroomed.

For­get about genes. We would halve the amount of emo­tional dis­tress in this coun­try if we had the more equal, rel­a­tively cohe­sive, less debt-​ridden polit­i­cal eco­nom­ics of our Euro­pean neighbours.

challenges to the biological/​genetic explanations for schizophrenia

Via Invol­un­tary Transformations

Schiz­o­phre­nia and Genet­ics— does crit­i­cal thought stop here? by Mary Boyle at a con­fer­ence enti­tled “From Gal­ton to the Human Genome Project: A crit­i­cal appraisal of genetic the­o­ries in psy­chol­ogy and psy­chi­a­try”, 2004

Mary Boyle is Emer­i­tus Pro­fes­sor of Clin­i­cal Psy­chol­ogy, Uni­ver­sity of East Lon­don and the author of Schiz­o­phre­nia: A Sci­en­tific Delusion?

psychiatry: Stop-​DSM

ED-AL012_satel_G_20100218172114

David Gothard

Stop-​DSM

HAVING IT OUT ONCE AND FOR ALL WITH THE DSM

MENTAL HEALTH SHOULD NO LONGER REFER TOSINGLE TEXTBOOK REQUIRED BY THE WHO.

The nomen­cla­ture of the DSM, on which WHO’s ICD-​10 has been mod­eled, has pro­gres­sively become the sin­gle and oblig­a­tory clas­si­fi­ca­tory ref­er­ence of “men­tal disorders”:

- in epidemiology;

- in the field of research and sci­en­tific publications;

- for social pro­tec­tion sys­tems and insurances;

- in order to col­lect sta­tis­ti­cal data for care pol­icy and financing;

- as an unique ref­er­ence man­ual in the teach­ing of psy­chi­a­try in med­ical and psy­chol­ogy schools, for the train­ing of pro­fes­sion­als and lec­tur­ers in health, social and spe­cial edu­ca­tion fields;

- finally, for physi­cians, who, hav­ing no other rel­e­vant train­ing, pre­scribe more and more psy­chotropic drugs, based on ques­tion­able diag­nos­tic criteria.

With the pur­pose of respond­ing to spe­cific and dis­tinct require­ments, the wide­spread use of this unique clas­si­fi­ca­tion becomes a con­fu­sion, inad­e­quacy and risks source. Espe­cially since the WHO is not empow­ered to take deci­sions on sci­en­tific research, but instead it should rec­om­mend inde­pen­dence, diver­sity and pro­mote the coex­is­tence of dif­fer­ent approaches.

More­over, far short of sci­en­tific rigor, the DSM is based on unam­bigu­ously par­tial con­cep­tions. It neglects the clin­i­cal data, mul­ti­plies the patho­log­i­cal cat­e­gories and low­ers the thresh­old of diag­nos­tic cri­te­ria for inclu­sion, which leads to false-​positives and pseudo-​outbreaks (as, for exam­ple, hyper­ac­tiv­ity, bipo­lar dis­or­der or autism). It is mis­used for pre­dic­tive pur­poses in chil­dren and ado­les­cents, tak­ing the risk of harm­ing their devel­op­ment and inte­gra­tion. It also pro­motes what has become, for a large part of the pop­u­la­tion, a real addic­tion to psy­chotropic drugs.

We are on the thresh­old of the DSM-V’s edi­tion, which will increase again the num­ber of cat­e­gories, already over­crowded, and extend the scope of pre­dic­tion. We can­not let it estab­lish such an ori­en­ta­tion, designed to increase arti­fi­cially the num­ber of pathologies.

medical illnesses misdiagnosed as mental illnesses.

inca panimage by inca pan

Con­fus­ing Med­ical Ail­ments with Men­tal Illness

An elderly woman’s sud­den depres­sion turns out to be a side effect of her high blood-​pressure medication.

A new mother’s exhaus­tion and dis­in­ter­est in her baby seem like post­par­tum depres­sion — but actu­ally sig­nal a post­par­tum thy­roid imbal­ance that med­ica­tion can correct.

A middle-​aged man­ager has angry out­bursts at work and fre­quently feels “ready to explode.” A brain scan reveals temporal-​lobe seizures, a type of epilepsy that can be treated with surgery or medication.

More than 100 med­ical dis­or­ders can mas­quer­ade as psy­cho­log­i­cal con­di­tions, accord­ing to Har­vard psy­chi­a­trist Bar­bara Schild­krout, who cited these exam­ples among oth­ers in “Unmask­ing Psy­cho­log­i­cal Symp­toms,” a book aimed at help­ing ther­a­pists broaden their diag­nos­tic skills.

More than 100 med­ical dis­or­ders can mas­quer­ade as psy­cho­log­i­cal con­di­tions or con­tribute to them, com­pli­cat­ing treat­ment decisions.

bio-​bio-​bio-​psychiatry. over-​prescribing. hubris.

fighting-stigma1
Psy­chi­a­try by Num­bers by melody at the Cargo Cult Con­trar­ian blog at the on-​line mag­a­zine the Sci­en­tific American

Two years ago, Camille went to her local health­care clinic com­plain­ing of gen­eral anx­i­ety and sleep prob­lems, hop­ing to be seen by a ther­a­pist. Instead, within a month, her psy­chi­a­trist had pre­scribed her five drugs to help reg­u­late her mood: Adder­all (a stim­u­lant), Ati­van (an anti-​anxiety med­ica­tion), Celexa (an anti-​depressant), Tra­zodone (a sleep aid and anti-​depressant), and Yazmin (hor­monal birth con­trol). Since she did not meet the cri­te­ria for a major psy­chi­atric dis­or­der, such as bipo­lar or schiz­o­phre­nia, she has never seen a ther­a­pist. Since that time, she has become addicted to Ati­van, and has suf­fered severe with­drawal the few times she has tried to go off it. Her weight has plum­meted. She has dif­fi­culty dis­tin­guish­ing wak­ing life from dreams. The prob­lems she hoped to resolve in ther­apy remain largely unresolved…

…What trou­bles us about these sto­ries is the way that the tan­gled skein of human lives are reduced down to symp­toms, while cause and con­text are for­got­ten or out­right ignored. To give a phys­i­cal anal­ogy: I might feel a sharp pain in my lower calf because I have ‘flesh-​eating’ necro­tiz­ing fasci­itis. Or it may be that I have badly strained a mus­cle after a par­tic­u­larly stren­u­ous work-​out. In one case, intra­venous antibi­otics and surgery are called for; in the other, an ibupro­fen and a mas­sage would do the trick just fine. Even a physi­cian fac­ing a moti­vated hypochon­driac could tell the dif­fer­ence. But lis­ten­ing to how psy­chotropic drugs are pre­scribed, one comes away with the uncom­fort­able feel­ing that when it comes to dis­or­ders of the mind, many doc­tors sim­ply can’t tell the dif­fer­ence. And they’re not being paid to.

psychiatry. drug industry. astroturfing.

Mental illness
rosen­berg and pringle— what a team

Astro­turf orga­ni­za­tions pro­mot­ing drugs for “men­tal illness”

Authors of the Jour­nal of the Amer­i­can Acad­emy of Child and Ado­les­cent Psychiatry’s influ­en­tial 2007 drug guide­lines for very young chil­dren – “this will some­times involve the use of med­ica­tions,” they pre­sell – also had Pharma ties. Finan­cial links were dis­closed to Abbott, AstraZeneca, Boehringer-​Ingelheim, Bristol-​Myers Squibb, Cephalon, Eli Lilly, For­est Labs, Glax­o­SmithK­line (GSK), sev­eral divi­sions of John­son & John­son, and ten other drug com­pa­nies. In 2012 alone the Acad­emy received $221,000 from Eli Lilly for research, an “out­reach pro­gram” and a con­fer­ence reception.

and

Another group widely viewed as a Pharma front is the Amer­i­can Foun­da­tion for Sui­cide Pre­ven­tion, ded­i­cated to stamp­ing out sui­cide caused by defi­cien­cies of the drugs it pro­motes. Sui­cide pre­ven­tion is a knee-​jerk mar­ket­ing tool for Pharma even though sui­cides are ris­ing, not falling, despite the 400 per­cent increase in its heav­ily pro­moted anti­de­pres­sants; it now accounts for 36,000 deaths a year. Hello?

and

Another iffy group is the National Coun­cil for Com­mu­nity Behav­ioral Health­care, described as “a non-​profit asso­ci­a­tion rep­re­sent­ing 1,300 men­tal health and addic­tions treat­ment and reha­bil­i­ta­tion orga­ni­za­tions,” on its web­site but tak­ing at least a half a mil­lion dol­lars in Pharma grants. In 2010, the Coun­cil received $190,000, from Eli Lilly and $500,000 from AstraZeneca. Nice non-​profit work if you can get it. The pre­vi­ous year the group received fund­ing from AstaZeneca and Bristol-​Myers Squibb, accord­ing to its magazine.

and Con­tinue read­ing

new drug approval. zoloft. flawed studies. lawsuit.

Zoloft_Shark

A dis­cus­sion of zoloft aproval zoloft, the approval, part I by mickey nardo (retired psy­chi­a­trist) with an analy­sis of the flawed data used for that approval. Laura A. Plum­lee has filed a suit against Pfizer, claim­ing that

1. Zoloft’s drug label. between 1991 to the present, was mis­lead­ing or decep­tive because it did not con­tain mate­r­ial infor­ma­tion about Zoloft’s effi­cacy, to wit, the drug label failed to pro­vide infor­ma­tion about the major­ity of clin­i­cal tri­als demon­strat­ing that Zoloft was no more effec­tive than placebo in treat­ing depres­sion and spec­ify the mar­ginal ben­e­fit to treat­ing depres­sion observed in the two clin­i­cal tri­als pur­port­ing to show Zoloft’s efficacy;

2. Pfizer inten­tion­ally, delib­er­ately, or reck­lessly cre­ated and dis­trib­uted Zoloft’s mis­lead­ing drug label with regard to its effi­cacy descrip­tion for depression.

Pfizer sub­mit­ted its new drug appli­ca­tion [“NDA”] to the FDA in 1990. As part of the appli­ca­tion, six placebo con­trolled tri­als were pre­sented to the FDA. Of the six clin­i­cal tri­als, four showed that Zoloft was no more effec­tive than placebo in treat­ing depres­sion and two indi­cated that Zoloft had slight pos­i­tive impact on depres­sion. The two stud­ies that showed that Zoloft was more effec­tive than placebo in treat­ing depres­sion, how­ever, were severely flawed.
In the first trial that sup­pos­edly demon­strated effi­cacy, researchers enrolled 369 patients in a double-​blind trial to test the effi­cacy of Zoloft at 50mg, 100mg, and 200mg against placebo. Within the treat­ment groups, i.e., those tak­ing Zoloft and not placebo, about 50% of the patients quit before the trial was completed-​22% because of side-​effects, 18% because it was not effec­tive, and 10% for unex­plained rea­sons. This large drop-​out rate reduced the avail­able patient pop­u­la­tion to 191. Of the remain­ing 50%, i. e., the pop­u­la­tion that did not quit Zoloft, the trial tracked patient changes in depres­sion based on the Hamil­ton Rat­ing Scale for Depres­sion [“HAM-​D”] over the course of six weeks…

Dr. Nardo filed a FOIA request for the New Drug Approval doc­u­ments and after crunch­ing some num­bers concludes

There’s plenty more to be gleaned from these doc­u­ments, but I’m going to take a break. This is enough to show the extent of the jury-​rigging of a Clin­i­cal Trial report from twenty-​five years ago, the dawn of time for the era of new psy­chophar­ma­col­ogy in psychiatry.

psychiatry. over-​diagnosis. dsm-​5.

pill

dsm-5…ignore its ten worst changes by allen j. fran­cis, md

1) Dis­rup­tive Mood Dys­reg­u­la­tion Dis­or­der: DSM 5 will turn tem­per tantrums into a men­tal dis­or­der– a puz­zling deci­sion based on the work of only one research group. We have no idea what­ever how this untested new diag­no­sis will play out in real life prac­tice set­tings, but my fear is that it will exac­er­bate, not relieve, the already exces­sive and inap­pro­pri­ate use of med­ica­tion in young chil­dren. Dur­ing the past two decades, child psy­chi­a­try has already pro­voked three fads– a tripling of Atten­tion Deficit Dis­or­der, a more than twenty-​times increase in Autis­tic Dis­or­der, and a forty-​times increase in child­hood Bipo­lar Dis­or­der. The field should have felt chas­tened by this sorry track record and should engage itself now in the cru­cial task of edu­cat­ing prac­ti­tion­ers and the pub­lic about the dif­fi­culty of accu­rately diag­nos­ing chil­dren and the risks of over– med­icat­ing them. DSM 5 should not be adding a new dis­or­der likely to result in a new fad and even more inap­pro­pri­ate med­ica­tion use in vul­ner­a­ble children.

2) Nor­mal grief will become Major Depres­sive Dis­or­der, thus med­ical­iz­ing and triv­i­al­iz­ing our expectable and nec­es­sary emo­tional reac­tions to the loss of a loved one and sub­sti­tut­ing pills and super­fi­cial med­ical rit­u­als for the deep con­so­la­tions of fam­ily, friends, reli­gion, and the resiliency that comes with time and the accep­tance of the lim­i­ta­tions of life.

3) The every­day for­get­ting char­ac­ter­is­tic of old age will now be mis­di­ag­nosed as Minor Neu­rocog­ni­tive Dis­or­der, cre­at­ing a huge false pos­i­tive pop­u­la­tion of peo­ple who are not at spe­cial risk for demen­tia. Since there is no effec­tive treat­ment for this ‘con­di­tion’ (or for demen­tia), the label pro­vides absolutely no ben­e­fit (while cre­at­ing great anx­i­ety) even for those at true risk for later devel­op­ing demen­tia. It is a dead loss for the many who will be mis­la­beled.
Con­tinue read­ing

psychiatry. misdiagnosis. somatic symptom disorder.

1047639-Cartoon-Black-And-White-Outline-Design-Of-A-Patient-With-An-Arrow-Through-His-Head-In-A-Psychiatrists-Office-Poster-Art-Print

somatic symp­tom dis­or­der could cap­ture mil­lions more under men­tal health diag­no­sis by suzy chapman

The SSD Work Group is propos­ing to rename the Somato­form Dis­or­ders sec­tion of DSM-​IV to “Somatic Symp­tom Dis­or­ders,” elim­i­nate four exist­ing DSM-​IV cat­e­gories: som­a­ti­za­tion dis­or­der [300.81], hypochon­dri­a­sis [300.7], pain dis­or­der*, and undif­fer­en­ti­ated somato­form dis­or­der [300.82] and replace them with a sin­gle new cat­e­gory – “Somatic Symp­tom Disorder.”

If approved, these pro­pos­als will license the appli­ca­tion of a men­tal health diag­no­sis for all ill­nesses – whether “estab­lished gen­eral med­ical con­di­tions or dis­or­ders” like dia­betes, heart dis­ease and can­cer or con­di­tions pre­sent­ing with “somatic symp­toms of unclear etiology” – if the clin­i­cian con­sid­ers the patient is devot­ing too much time to their symp­toms and that their life has become “sub­sumed” by health con­cerns and pre­oc­cu­pa­tions, or their response to dis­tress­ing somatic symp­toms is “exces­sive” or “dis­pro­por­tion­ate,” or their cop­ing strate­gies “maladaptive.”

• Appli­ca­tion of highly sub­jec­tive and dif­fi­cult to mea­sure cri­te­ria could poten­tially result in mis­di­ag­no­sis with a men­tal health dis­or­der, mis­ap­pli­ca­tion of an addi­tional diag­no­sis of a men­tal health dis­or­der or missed diag­noses through dis­missal and fail­ure to inves­ti­gate new or wors­en­ing somatic symptoms.

• Patients with can­cer and life threat­en­ing dis­eases may be reluc­tant to report new symp­toms that might be early indi­ca­tors of recur­rence, metas­ta­sis or sec­ondary dis­ease for fear of attract­ing a diag­no­sis of “SSD” or of being labelled as “catastrophisers.”

• Appli­ca­tion of an addi­tional diag­no­sis of Somatic Symp­tom Dis­or­der may have impli­ca­tions for the types of med­ical inves­ti­ga­tions, tests and treat­ments that clin­i­cians are pre­pared to con­sider and which insur­ers are pre­pared to fund.

• Appli­ca­tion of an addi­tional diag­no­sis of Somatic Symp­tom Dis­or­der may impact pay­ment of employ­ment, med­ical and dis­abil­ity insur­ance and the length of time for which insur­ers are pre­pared to pay out. It may neg­a­tively influ­ence the per­cep­tions of agen­cies involved with the assess­ment and pro­vi­sion of social care, dis­abil­ity adap­ta­tions, edu­ca­tion and work­place accommodations.

• Patients pre­scribed psy­chotropic drugs for per­ceived unrea­son­able lev­els of “ill­ness worry” or “exces­sive pre­oc­cu­pa­tion with symp­toms” may be placed at risk of iatro­genic dis­ease or sub­jected to inap­pro­pri­ate behav­ioural therapies.

• For multi-​system dis­eases like Mul­ti­ple Scle­ro­sis, Behçet’s syn­drome or Sys­temic lupus it can take sev­eral years before a diag­no­sis is arrived at. In the mean­time, patients with chronic, mul­ti­ple somatic symp­toms who are still wait­ing for a diag­no­sis would be vulnerable.

• The bur­den of the DSM-​5 changes will fall par­tic­u­larly heav­ily upon women who are more likely to be casu­ally dis­missed when pre­sent­ing with phys­i­cal symp­toms and more likely to receive inap­pro­pri­ate anti­de­pres­sants and anti anx­i­ety med­ica­tions for them.

• Pro­pos­als allow for the appli­ca­tion of a diag­no­sis of Somatic Symp­tom Dis­or­der where a par­ent is con­sid­ered exces­sively con­cerned with a child’s symp­toms [3]. Fam­i­lies car­ing for chil­dren with any chronic ill­ness may be placed at increased risk of wrong­ful accu­sa­tion of “over-​involvement” with a child’s symptomatology.

Where a par­ent is per­ceived as encour­ag­ing main­te­nance of “sick role behav­iour” in a child, this may pro­voke social ser­vices inves­ti­ga­tion or court inter­ven­tion for removal of a sick child out of the home envi­ron­ment and into fos­ter care or enforced in-​patient “reha­bil­i­ta­tion.” This is already hap­pen­ing in fam­i­lies with a child or young per­son with chronic ill­ness, notably with Chronic fatigue syn­drome or ME. It may hap­pen more fre­quently with a diag­no­sis of a chronic child­hood ill­ness + SSD.

psychiatry. psychoactive drugs. research.

NYT(TRartColor)science2-24-12

illus­tra­tion by tim robin­son

no new meds

Well, at least the arti­cle expresses this:

Psy­chi­a­trists and neu­ro­sci­en­tists around the world recently have begun sound­ing the alarm that the field is in cri­sis. Drug devel­op­ment for com­plex psy­chi­atric ill­nesses is mis­guided, they argue, stuck churn­ing out slight vari­a­tions on ther­a­peu­tic themes that didn’t work all that well to begin with. Faulty assump­tions, ani­mal mod­els that don’t look any­thing like human dis­eases, hazy diag­noses and a lack of knowl­edge about how the brain works have all thwarted the search for bet­ter drugs.

But then it goes on to say that they need a bet­ter under­stand­ing of genes and mol­e­cules in order to under­stand why “1 out of 4 peo­ple are men­tally ill” and why so many peo­ple suf­fer from men­tal afflic­tion, in their opin­ion. With 1 out of 4 as an esti­mate, how could envi­ron­ment be an issue? How could any of the diag­noses be bunk? Yes. Snark.